Surgery Alone for Localized Neuroblastoma
Author Information
Author(s): De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R, Laureys G, Beck-Popovic M, de Lacerda A F, Pearson A D J, De Kraker J, Ambros P F, de Rycke Y, Conte M, Bruzzi P, Michon J
Primary Institution: Giannina Gaslini Children's Hospital, Genova, Italy
Hypothesis
Is surgery alone an effective and safe treatment for localized resectable neuroblastoma except stage 2 with amplified MYCN gene?
Conclusion
Surgery alone yielded excellent overall survival for both stage 1 and 2 neuroblastoma without MYCNA, although stage 2 patients with unfavorable histopathology and elevated LDH suffered a high number of relapses.
Supporting Evidence
- 411 out of 427 eligible patients had normal MYCN gene status.
- 5-year relapse-free survival (RFS) rate for stage 1 patients was 94.3%.
- 5-year overall survival (OS) rate for stage 1 patients was 98.9%.
- 22 out of 123 stage 2 patients relapsed, with a 5-year RFS of 82.8%.
- Patients with unfavorable histopathology had significantly worse OS and RFS.
Takeaway
Doctors found that just doing surgery can help kids with a certain type of cancer called neuroblastoma do really well, but some kids still have problems if their cancer is more complicated.
Methodology
The study involved registering children with localized neuroblastoma, assessing MYCN gene status, and following up on their outcomes after surgery.
Limitations
The study had a small number of events for some analyses, limiting the ability to draw firm conclusions about certain prognostic factors.
Participant Demographics
The study included 427 children with localized resectable neuroblastoma, with a slight male predominance among stage 1 patients.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 91.6–97.0 for RFS in stage 1; 95% CI: 76.2–89.5 for RFS in stage 2
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website